- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05794568
Evaluate the Efficacy of the OITcontrol Application.
Multicenter, Open, Controlled, Randomized Study to Evaluate the Efficacy of the OITcontrol Application in Monitoring Patients in OIT With Food.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Evaluate the quality of life of patients with respect to their food allergy by analyzing the data from the FAQLQ-CF and/or SFAQoL-PF questionnaires.
- Evaluate the perception of patients on the quality and safety of hospital care through the analysis of the adapted SERVQHOS questionnaire and the "Evolution of the perception of patients on the safety of health services".
Evaluate patient safety with OITcontrol based on:
- Number of reactions in the hospital,
- Number of reactions outside the hospital,
- Compliance with the information and recommendations by the patient:
i. recording shots, ii. reaction log, iii. discordances between the medication used and prescribed after a reaction, iv. avoidance of cofactors.
Evaluate the consumption of health resources regarding the use, derived from the OIT of the following resources:
- Number of extraordinary visits to the allergy department,
- Number of phone calls for questions,
- Number of visits to the emergency department.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maria José Goikoetxea Lapresa
- Phone Number: 651143974
- Email: mjgoiko@unav.es
Study Locations
-
-
-
Madrid, Spain, 28009
- Hospital Gregorio Marañón
-
Madrid, Spain, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, Spain, 28031
- Hospital Infanta Leonor
-
Madrid, Spain, 28010
- Hospital Clinico San Carlos
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28922
- Hospital Fundación Alcorcón
-
Leganés, Madrid, Spain, 28911
- Hospital Severo Ochoa
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Universidad de Navarra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient must be between 4 and 12 years old at the time of informed consent.
- Patients diagnosed with food allergy to eggs and/or milk (clinical history compatible with IgE-mediated reaction with egg or milk together with positive specific IgE against egg white or milk (>0.35kU/L) and/or skin test by intraepidermal puncture equal to or similar to 3mm for egg white or milk); in case of egg allergy, patients may be allergic to raw or undercooked egg despite their tolerance to well-cooked egg.
- The patient, or their legally authorized representative, has given their consent to participate in the study.
- The patient, or his legally authorized representative, has accepted the OIT treatment after the explanation of its risks and benefits and the requirements for the maintenance phase.
- The patient must, in the opinion of the investigator, be able to meet all the requirements of the study.
- The patient, or their legally authorized representative, who assumes the OIT treatment at home, has a Smartphone with internet access via mobile data and/or Wi-Fi available at home.
- Reaction with the OIT allergen in the controlled oral provocation test (POC) included in the initial phase of treatment.
Exclusion Criteria:
Present any of the OIT exclusion criteria:
- Allergy to cow's milk and/or eggs not mediated by IgE.
- Uncontrolled asthma. In the case of a patient with asthma, this must be controlled before the start of OIT.
- Severe atopic dermatitis.
- Previous diagnosis of eosinophilic esogaphitis.
- Inflammatory bowel disease.
- Mastocytosis.
- Immunocompromised patients.
- Disorders and/or treatments in which the use of adrenaline is contraindicated.
- Difficulty understanding the risks and benefits of the procedure, and social and family factors that may compromise long-term maintenance therapy. This includes conflicts between parents or legal representatives that may adversely affect treatment.
- Inability of parents or legal representative to follow instructions, identify reactions, or administer medication (especially auto-injectable adrenaline).
- Previous allergic reaction with the corresponding OIT food within the month prior to the initial visit.
- Treatment with omalizumab or any other immunomodulatory biologic drug within the three months prior to the initial visit.
- Pregnant women, or women of childbearing potential not using a safe means of contraception (abstinence is considered an acceptable method) during the entire study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: OITcontrol group
|
App to monitor OIT patients
|
No Intervention: paperPRO group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effectiveness of OITcontrol as an application to improve the quality of life.
Time Frame: 12 weeks
|
Improve the quality of life of patients, as well as their perception of the quality and safety of hospital care, safety and the reduction of the consumption of health resources in patients under OITcontrol.
|
12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OITcontrol_QL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Food Allergy in Children
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Stanford UniversityRecruitingFood Allergy | Food Allergy in ChildrenUnited States
-
Rhode Island HospitalCompletedFood Allergy in Children
-
Children's National Research InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Northwestern... and other collaboratorsRecruiting
-
Federico II UniversityRecruiting
-
Rhode Island HospitalVirtually Better, Inc.CompletedFood Allergy in Children
-
Chinese University of Hong KongRecruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
Clinical Trials on OITcontrol app monitoring
-
Imperial College Healthcare NHS TrustImperial College London; University College, London; patientMpower Ltd.; Action...RecruitingInterstitial Lung DiseaseUnited Kingdom
-
Shirley Ryan AbilityLabRecruitingMultiple Sclerosis | Parkinson DiseaseUnited States
-
Rambam Health Care CampusNot yet recruitingGestational Diabetes Mellitus
-
Federico II UniversityRecruitingHeart Failure | Sudden Cardiac Death | Cardiac ArrhythmiasItaly
-
Ggz Oost BrabantUniversity of Groningen; Accare; Amsterdam UMC, location AMC; RINO ZUIDRecruitingDepressive Disorder | Anxiety DisordersNetherlands
-
Akdeniz UniversityAntalya Training and Research HospitalRecruitingQuality of Life | Obesity | Complication | eHealth | Bariatric Surgery | Mobile Health | Self ManagementTurkey
-
Second Affiliated Hospital, School of Medicine,...Shaoxing Gaobu Street Community Health Service Center; Shaoxing Mashan Street... and other collaboratorsCompletedStroke | Cognitive Impairment | DementiaChina
-
Women and Infants Hospital of Rhode IslandCompletedPreeclampsia | Gestational Hypertension | Chronic Hypertension Complicating PregnancyUnited States
-
Singapore General HospitalSengkang General Hospital; National Heart Centre SingaporeRecruitingDiabetes Mellitus, Type 2Singapore
-
Soledad Ruiz de AdanaUnknownDiabetes Mellitus, Type 1Spain